Literature DB >> 3231904

Study of immune complexes in bronchoalveolar lavage fluids.

P P Dall'Aglio1, A Pesci, G Bertorelli, E Brianti, S Scarpa.   

Abstract

Immune complexes (IC) were investigated in the bronchoalveolar lavage fluid (BAL) of 5 patients with hypersensitivity pneumonitis (HP), 11 with idiopathic pulmonary fibrosis (IPF) and 16 with sarcoidosis (S) by three different methods: C1Q-BA, KgB, AKgB-MA. Using AKgB-MA, it is possible to identify the class of antibodies forming the IC. IC were present in all cases of HP, in 8/11 (73%) of IPF and in 10/16 (62%) of S. However, the three tests showed discordant results for the three different diseases: C1Q-BA and KgB-SP were both positive in 40%, AKgB-MA in 80% of HP cases; C1Q-BA in 73%, KgB-SP in 9% and AKgB-MA in 46% of IPF cases; C1Q-BA in 31%, KgB-SP in 12% and AKgB-MA in 31% of S cases. In all of the diseases, the IC were mostly composed of IgG; moreover, in HP IgA was also frequently present. The determination of IC in different fractions obtained from BAL ultracentrifugation, confirmed the simultaneous presence of IC of different molecular weights and antibody composition. Lung transbronchial biopsy with immunofluorescence showed immunoglobulin, prevalently IgG, and C, in all HP cases, the majority of IPF cases and 50% of S cases. This confirms the importance of IC in the pathogenesis and/or evolution of some pulmonary diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3231904     DOI: 10.1159/000195495

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  21 in total

Review 1.  Idiopathic pulmonary fibrosis and a role for autoimmunity.

Authors:  Gerard F Hoyne; Hannah Elliott; Steven E Mutsaers; Cecilia M Prêle
Journal:  Immunol Cell Biol       Date:  2017-03-30       Impact factor: 5.126

2.  Time course of bleomycin-induced lung fibrosis.

Authors:  G Izbicki; M J Segel; T G Christensen; M W Conner; R Breuer
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

3.  Rituximab in the treatment of refractory pulmonary sarcoidosis.

Authors:  Nadera J Sweiss; Elyse E Lower; Mehdi Mirsaeidi; Steven Dudek; Joe G N Garcia; David Perkins; Patricia W Finn; Robert P Baughman
Journal:  Eur Respir J       Date:  2014-01-31       Impact factor: 16.671

4.  Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease.

Authors:  Jon T Giles; Sonye K Danoff; Jeremy Sokolove; Catriona A Wagner; Robert Winchester; Dimitrios A Pappas; Stanley Siegelman; Geoff Connors; William H Robinson; Joan M Bathon
Journal:  Ann Rheum Dis       Date:  2013-05-28       Impact factor: 19.103

5.  Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.

Authors:  Jianmin Xue; Daniel J Kass; Jessica Bon; Louis Vuga; Jiangning Tan; Eva Csizmadia; Leo Otterbein; Makoto Soejima; Marc C Levesque; Kevin F Gibson; Naftali Kaminski; Joseph M Pilewski; Michael Donahoe; Frank C Sciurba; Steven R Duncan
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

6.  B lymphocyte accumulations in human pulmonary sarcoidosis.

Authors:  S B Fazel; S E Howie; A S Krajewski; D Lamb
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

Review 7.  New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis.

Authors:  M N Sheppard; N K Harrison
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

8.  Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.

Authors:  Rehan A Kahloon; Jianmin Xue; Arpit Bhargava; Eva Csizmadia; Leo Otterbein; Daniel J Kass; Jessica Bon; Makoto Soejima; Marc C Levesque; Kathleen O Lindell; Kevin F Gibson; Naftali Kaminski; Gunjan Banga; Chester V Oddis; Joseph M Pilewski; Frank C Sciurba; Michael Donahoe; Yingze Zhang; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2013-04-01       Impact factor: 21.405

9.  C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.

Authors:  Louis J Vuga; John R Tedrow; Kusum V Pandit; Jiangning Tan; Daniel J Kass; Jianmin Xue; Divay Chandra; Joseph K Leader; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

10.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.